山楂及其药对改善代谢相关脂肪性肝病的药理作用机制

管雅捷; 张琪振; 吴文静; 崔蓓蕾; 徐俊姣; 宋艺佳; 赵文霞; 刘鸣昊

doi:10.12449/JCH260927

山楂及其药对改善代谢相关脂肪性肝病的药理作用机制

DOI: 10.12449/JCH260927

管雅捷^{1, 2},
张琪振^{1, 2},
吴文静^{1, 2},
崔蓓蕾^{1, 2},
徐俊姣^{1, 2},
宋艺佳^{1, 2},
赵文霞^{1, 3, 4, 5},
刘鸣昊^{1, 3, 4, 5, , ,}

1.
河南中医药大学第一附属医院肝病（脾胃）诊疗中心，郑州 450000
2.
河南中医药大学第一临床医学院，郑州 450046
3.
河南省中医药科学院，郑州 450000
4.
中西医防治重大疾病河南省协同创新中心，郑州 450000
5.
豫药全产业链研发河南省协同创新中心，郑州 450000

基金项目:

国家自然科学基金 (82575010);

国家自然科学基金 (81904154);

国家自然科学基金 (82205086);

河南省科技攻关计划 (242102310500);

河南省科技攻关计划 (232102310438);

河南省卫生健康委中医药传承创新专项 (2023ZXZX1162);

河南省卫生健康委员会国家中医临床研究基地科研专项 (2022JDZX114);

河南省“双一流”创建学科中医学科学研究专项 (HSRP-DFCTCM-2023-1-10)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：管雅捷负责设计论文框架，起草论文；张琪振、吴文静、崔蓓蕾和徐俊姣负责搜集相关文献；宋艺佳负责论文修改；赵文霞、刘鸣昊负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
刘鸣昊， liumh015@163.com （ORCID： 0009-0001-7712-4605）

计量
- 文章访问数: 17
- HTML全文浏览量: 4
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2026-01-28
- 录用日期: 2026-02-09
- 出版日期: 2026-09-25

Pharmacological mechanism of hawthorn fruit and its herb pairs for improving metabolic dysfunction-associated fatty liver disease

Yajie Guan^{1, 2},
Qizhen Zhang^{1, 2},
Wenjing Wu^{1, 2},
Beilei Cui^{1, 2},
Junjiao Xu^{1, 2},
Yijia Song^{1, 2},
Wenxia Zhao^{1, 3, 4, 5},
Minghao Liu^{1, 3, 4, 5
, ,
,}

1.
Liver Disease （Spleen & Stomach） Diagnosis and Treatment Center，The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450000，China
2.
The First Clinical Medical College of Henan University of Chinese Medicine，Zhengzhou 450046，China
3.
Henan Academy of Traditional Chinese Medicine，Zhengzhou 450000，China
4.
Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine，Henan Province，Zhengzhou 450000，China
5.
Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao，Henan Province，Zhengzhou 450000，China

Research funding:

National Natural Science Foundation of China (82575010);

National Natural Science Foundation of China (81904154);

National Natural Science Foundation of China (82205086);

Henan Provincial Science and Technology Program (242102310500);

Henan Provincial Science and Technology Program (232102310438);

Special Project on Inheritance and Innovation in Traditional Chinese Medicine by the Henan Health Commission (2023ZXZX1162);

Henan Provincial Health Commission National Clinical Research Base of Traditional Chinese Medicine Scientific Research Project (2022JDZX114);

Scientific Research Special Project under the “Double First-Class” Initiative for Traditional Chinese Medicine in Henan Province (HSRP-DFCTCM-2023-1-10)

More Information

Corresponding author: Liu Minghao， liumh015@163.com （ORCID： 0009-0001-7712-4605）

摘要

摘要: 代谢相关脂肪性肝病（MAFLD）已成为全球首要的慢性肝脏疾病。山楂作为经典的药食同源中药，具有消食化积、活血化瘀的功效。现代药理学研究表明，山楂及其活性成分在调节脂质代谢、改善胰岛素抵抗、抑制炎症反应、延缓肝纤维化及保护肝细胞等方面展现出多元药理活性，精准契合MAFLD“多重打击”的病理特征，在MAFLD的防治中展现出显著优势。药对配伍是中医药发挥增效减毒作用的关键策略。临床实践中，常将山楂与丹参、泽泻、决明子和茯苓等药物配伍，通过“相须相使”增强疗效，拓展其在MAFLD不同证型中的应用。本文系统梳理了山楂干预MAFLD的核心药理机制及其经典药对的研究进展，旨在为山楂及其配伍的深度开发与MAFLD的临床精准干预提供科学参考。
- 山楂 /
- 药对配伍 /
- 代谢相关脂肪性肝病 /
- 药理机制
Abstract: Metabolic dysfunction-associated fatty liver disease （MAFLD） has become the leading chronic liver disease worldwide. As a classic food-medicine homologous Chinese herb， hawthorn fruit has the functions of promoting digestion to resolve food stagnation and activating blood circulation to resolve blood stasis. Modern pharmacological studies have shown that hawthorn fruit and its active components exert diverse pharmacological activities in regulating lipid metabolism， improving insulin resistance， inhibiting inflammatory response， delaying hepatic fibrosis， and protecting hepatocytes. These effects precisely match the “multiple-hit” pathological features of MAFLD， and thus hawthorn fruit shows significant advantages in the prevention and treatment of MAFLD. Drug pair combination is a key strategy in traditional Chinese medicine to enhance efficacy and reduce toxicity. In clinical practice， hawthorn fruit is often combined with Salvia miltiorrhiza， Alisma orientalis， cassia seed， and Poria cocos， and such combination adheres to the principle of “mutual reinforcement and assistance” to enhance efficacy and expand their application in different syndromes of MAFLD. This article systematically reviews the core pharmacological mechanisms of hawthorn fruit in intervening against MAFLD and the research advances in its classic drug combinations， in order to provide a scientific reference for the in-depth development of hawthorn fruit and its combinations and the precise clinical intervention of MAFLD.
- Hawthorn /
- Herb Pairing /
- Metabolic Dysfunction-Associated Fatty Liver Disease /
- Pharmacological Mechanism

HTML全文

图 1 山楂的主要活性成分与药理作用

Figure 1. Active constituents and pharmacological effects of hawthorn

下载: 全尺寸图片幻灯片

图 2 山楂药对干预代谢相关脂肪性肝病的药理机制

Figure 2. Therapeutic mechanisms of a hawthorn-based therapy against metabolic dysfunction-associated fatty liver disease

下载: 全尺寸图片幻灯片

参考文献(34)

[1]	Liu S W, Chang X D, Liu X F, et al. Effects of pretreatments on anthocyanin composition, phenolics contents and antioxidant capacities during fermentation of hawthorn(Crataegus pinnatifida) drink[J]. Food Chem, 2016, 212: 87- 95. DOI: 10.1016/j.foodchem.2016.05.146.
[2]	Li C J, Chen Y E, Yuan X, et al. Vitexin ameliorates chronic stress plub high fat diet-induced nonalcoholic fatty liver disease by inhibiting inflammation[J]. Eur J Pharmacol, 2020, 882: 173264. DOI: 10.1016/j.ejphar.2020.173264.
[3]	Li Y H, Ye M H, He Q J, et al. Novel dual AMPK/NRF2 activation by leucocyanidin from Hawthorn(Crataegus) for mitochondria repair-Targeted therapy of hepatic steatosis[J]. Phytomedicine, 2026, 150: 157614. DOI: 10.1016/j.phymed.2025.157614.
[4]	Zhang Mingfa, Shen Yaqin. Research advances on effects of ursolic acid and oleanolic acid against hepatic steatosis and fibrosis[J]. Drug Eval Res, 2017, 40( 2): 270- 278. DOI: 10.7501/j.issn.1674-6376.2017.02.028. 张明发, 沈雅琴. 熊果酸和齐墩果酸抗肝脂肪变和纤维化作用研究进展[J]. 药物评价研究, 2017, 40( 2): 270- 278. DOI: 10.7501/j.issn.1674-6376.2017.02.028.
[5]	Sun Y, Meng X W, Chen M J, et al. Isolation, structural properties and bioactivities of polysaccharides from Crataegus pinnatifida[J]. J Ethnopharmacol, 2024, 323: 117688. DOI: 10.1016/j.jep.2023.117688.
[6]	Eghlima G, Aghamir F, Mohammadi M, et al. Bioactive compounds and antimicrobial activities in Iranian Crataegus persica ecotypes for potential food and medicinal uses[J]. Food Sci Nutr, 2025, 13( 1): e4748. DOI: 10.1002/fsn3.4748.
[7]	Zheng L P, Lu Z H, Ma Y R, et al. Hawthorn total flavonoids ameliorate hyperlipidemia through AMPK/SREBP1-c and PPARα/PGC-1α/CPT-1A pathway activation and gut microbiota modulation[J]. J Sci Food Agric, 2025, 105( 8): 4326- 4337. DOI: 10.1002/jsfa.14188.
[8]	Gao Z Q, Xie M J, Zhou R Y, et al. Ameliorative effects of Monascus-fermented hawthorn extract on a high-fat diet-induced rat model of non-alcoholic fatty liver disease[J]. Heliyon, 2024, 10( 18): e37354. DOI: 10.1016/j.heliyon.2024.e37354.
[9]	Yang H, Yang T T, Heng C, et al. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice[J]. Phytother Res, 2019, 33( 12): 3140- 3152. DOI: 10.1002/ptr.6486.
[10]	Yu Q H, Chen X J, Sun X, et al. Pectic oligogalacturonide facilitates the synthesis and activation of adiponectin to improve hepatic lipid oxidation[J]. Mol Nutr Food Res, 2021, 65( 20): e2100167. DOI: 10.1002/mnfr.202100167.
[11]	Gheitasi I, Savari F, Akbari G, et al. Molecular mechanisms of hawthorn extracts in multiple organs disorders in underlying of diabetes: A review[J]. Int J Endocrinol, 2022, 2022: 2002768. DOI: 10.1155/2022/2002768.
[12]	Liu S W, Yu J C, Fu M F, et al. Regulatory effects of hawthorn polyphenols on hyperglycemic, inflammatory, insulin resistance responses, and alleviation of aortic injury in type 2 diabetic rats[J]. Food Res Int, 2021, 142: 110239. DOI: 10.1016/j.foodres.2021.110239.
[13]	Gu W J, Wang R Q, Cai Z W, et al. Hawthorn total flavonoids ameliorate ambient fine particulate matter-induced insulin resistance and metabolic abnormalities of lipids in mice[J]. Ecotoxicol Environ Saf, 2023, 249: 114456. DOI: 10.1016/j.ecoenv.2022.114456.
[14]	Wang X X, Li X, Li L Y, et al. Hawthorn fruit extract ameliorates H₂O₂-induced oxidative damage in neuronal PC12 cells and prolongs the lifespan of Caenorhabditis elegans via the IIS signaling pathway[J]. Food Funct, 2022, 13( 20): 10680- 10694.
[15]	Hamza A A, Lashin F M, Gamel M, et al. Hawthorn herbal preparation from Crataegus oxyacantha attenuates in vivo carbon tetrachloride-induced hepatic fibrosis via modulating oxidative stress and inflammation[J]. Antioxidants(Basel), 2020, 9( 12): 1173. DOI: 10.3390/antiox9121173.
[16]	Mousa A M, Allemailem K S. Could hawthorn have a cardioprotective impact against obesity-induced cardiac injury in rats via antioxidant, hypolipidemic, anti-inflammatory, antiapoptotic, and antifibrotic properties?[J]. Tissue Cell, 2025, 93: 102673. DOI: 10.1016/j.tice.2024.102673.
[17]	Yue Caixia, Chen Lei, Wang Wenkui, et al. Maslinic acid protects against LPS-induced inflammatory response in RAW_264.7 cells by regulating phosphorylation of STAT3[J]. Food Mach, 2021, 37( 6): 36- 42. DOI: 10.13652/j.issn.1003-5788.2021.06.007. 岳彩霞, 陈磊, 王文魁, 等. 山楂酸调控STAT3磷酸化保护LPS致RAW_264.7细胞炎症反应的研究[J]. 食品与机械, 2021, 37( 6): 36- 42. DOI: 10.13652/j.issn.1003-5788.2021.06.007.
[18]	Liu S, Fang Y, Yu J, et al. Hawthorn polyphenols reduce high glucose-induced inflammation and apoptosis in ARPE-19 cells by regulating miR-34a/SIRT1 to reduce acetylation[J]. J Food Biochem, 2021, 45( 2): e13623. DOI: 10.1111/jfbc.13623.
[19]	Chen Xing. Extraction, purification, characterization and antioxidant activity of polysaccharides from Crataegus pinnatifida bunge[D]. Huai’an: Huai’an University, 2020. DOI: 10.27944/d.cnki.ghygy.2020.000019. 陈星. 山楂多糖的提取纯化、表征及其体外抗氧化活性研究[D]. 淮安: 淮阴工学院, 2020. DOI: 10.27944/d.cnki.ghygy.2020.000019.
[20]	Chang Jiahan, Cai Yujie, Hou Yixin, et al. Regulatory role of macrophage glycolysis in metabolic dysfunction-associated fatty liver disease[J]. J Clin Hepatol, 2025, 41( 10): 2130- 2135. DOI: 10.12449/JCH251025. 常嘉涵, 蔡玉洁, 侯艺鑫, 等. 巨噬细胞糖酵解在代谢相关脂肪性肝病中的调控作用[J]. 临床肝胆病杂志, 2025, 41( 10): 2130- 2135. DOI: 10.12449/JCH251025.
[21]	Zhou Bicong, Yang Ying. Mechanism of Shanzha(hawthorn)extract in regulating dyslipidemia by affecting T cells through NETs[J]. Chin Arch Tradit Chin Med, 2026, 44( 3): 55- 59. DOI: 10.13193/j.issn.1673-7717.2026.03.010. 周碧聪, 杨莺. 山楂提取物通过NETs影响T细胞调控血脂异常的作用机制研究[J]. 中华中医药学刊, 2026, 44( 3): 55- 59. DOI: 10.13193/j.issn.1673-7717.2026.03.010.
[22]	Huang Haoxiao, Yang Ying, Liu Ning. Effects of Shanzha(crataegi fructus) extract on Th1 and Th2 cell subsets in dyslipidemic mice based on modulation of TBX21 and GATA-3 factors[J]. Chin Arch Tradit Chin Med, 2024, 42( 12): 40- 46. DOI: 10.13193/j.issn.1673-7717.2024.12.009. 黄昊枭, 杨莺, 刘宁. 山楂提取物基于调控TBX21、GATA-3因子对血脂异常小鼠Th1、Th2细胞亚群的影响[J]. 中华中医药学刊, 2024, 42( 12): 40- 46. DOI: 10.13193/j.issn.1673-7717.2024.12.009.
[23]	Sun Hui, Fan Manlu, Lu Huan, et al. Research progress in the regulation of gut-liver axis microecology with traditional Chinese medicine in the treatment of metabolism-associated fatty liver disease[J]. J Changchun Univ Chin Med, 2026, 42( 3): 373- 378. DOI: 10.13463/j.cnki.cczyy.2026.03.023. 孙慧, 樊曼璐, 卢欢, 等. 中医药调控肠肝轴微生态治疗代谢相关脂肪性肝病研究进展[J]. 长春中医药大学学报, 2026, 42( 3): 373- 378. DOI: 10.13463/j.cnki.cczyy.2026.03.023.
[24]	Yang Xue, Zhang Xu, Xian Jin, et al. Mechanism of action of traditional Chinese medicine in treatment of nonalcoholic fatty liver disease based on intestinal microecology[J]. J Clin Hepatol, 2024, 40( 4): 804- 809. DOI: 10.12449/JCH240426. 杨雪, 张旭, 仙晋, 等. 基于肠道微生态探讨中医药治疗非酒精性脂肪性肝病的作用机制[J]. 临床肝胆病杂志, 2024, 40( 4): 804- 809. DOI: 10.12449/JCH240426.
[25]	Zhou Y, Wang M Y, Wang Z C, et al. Polysaccharides from hawthorn fruit alleviate high-fat diet-induced NAFLD in mice by improving gut microbiota dysbiosis and hepatic metabolic disorder[J]. Phytomedicine, 2025, 139: 156458. DOI: 10.1016/j.phymed.2025.156458.
[26]	Li T, Chen J B, Xu Y C, et al. Hawthorn pectin alleviates DSS-induced colitis in mice by ameliorating intestinal barrier function and modulating gut microbiota[J]. J Agric Food Chem, 2025, 73( 10): 5872- 5885. DOI: 10.1021/acs.jafc.4c07965.
[27]	Li J Y, Hu W J, Li C J, et al. Recent advances in hawthorn(Crataegus L.) polysaccharides for prevention and treatment of non-alcoholic fatty liver disease(NAFLD): A review[J]. Int J Biol Macromol, 2026, 336: 149403. DOI: 10.1016/j.ijbiomac.2025.149403.
[28]	Liu G C, Cui Z, Gao X Y, et al. Corosolic acid ameliorates non-alcoholic steatohepatitis induced by high-fat diet and carbon tetrachloride by regulating TGF-β1/Smad2, NF-κB, and AMPK signaling pathways[J]. Phytother Res, 2021, 35( 9): 5214- 5226. DOI: 10.1002/ptr.7195.
[29]	Chen X Y, Wang Y F, Wan J, et al. Quercetin alleviates liver fibrosis via regulating glycolysis of liver sinusoidal endothelial cells and neutrophil infiltration[J]. Biomol Biomed, 2024, 24( 6): 1806- 1815. DOI: 10.17305/bb.2024.10530.
[30]	Zhu Lixia, Wang Lisheng, Zhang Yingfeng. Study on serum lipid level, content of SOD and MDA of Salvia miltiorrhizae total Salvianolic acid and hawthorn flavonoids compatibility in hyperlipidemia rats[J]. China Med Her, 2014, 11( 20): 9- 12. 朱黎霞, 王利胜, 张英丰. 丹参总酚酸、山楂总黄酮组分配伍对高脂血症大鼠血脂、超氧化物歧化酶及丙二醛的影响[J]. 中国医药导报, 2014, 11( 20): 9- 12.
[31]	Wang H, Wang H, Zhang J, et al. Molecular mechanism of crataegi folium and Alisma Rhizoma in the treatment of dyslipidemia based on network pharmacology and molecular docking[J]. Evid Based Complementary Altern Med, 2022, 2022( 1): 4891370. DOI: 10.1155/2022/4891370.
[32]	Gao Hongru, Lu Bingjiu. Professor Lu bingjiu’s experience in treatment of fatty liver by hawthorn and rhizoma alismatis[J]. J Shaanxi Univ Chin Med, 2016, 39( 2): 23- 24, 102. DOI: 10.13424/j.cnki.jsctcm.2016.02.008. 高红如, 卢秉久. 卢秉久教授配伍运用山楂与泽泻治疗脂肪肝经验[J]. 陕西中医药大学学报, 2016, 39( 2): 23- 24, 102. DOI: 10.13424/j.cnki.jsctcm.2016.02.008.
[33]	Huang Y L, Chow C J, Tsai Y H. Composition, characteristics, and in-vitro physiological effects of the water-soluble polysaccharides from Cassia seed[J]. Food Chem, 2012, 134( 4): 1967- 1972. DOI: 10.1016/j.foodchem.2012.03.127.
[34]	Li Y J, Wang P Q, Yang H, et al. In vivo identification of bioactive components of Poria cocos for adjusting mitochondria against metabolic dysfunction-associated fatty liver disease[J]. Heliyon, 2024, 10( 16): e35645. DOI: 10.1016/j.heliyon.2024.e35645.